{
    "clinical_study": {
        "@rank": "101031", 
        "brief_summary": {
            "textblock": "The objective is to determine the effect of Isoprinosine (inosine pranobex) in homosexual\n      male patients with AIDS related complex (ARC) in delaying the onset of AIDS. Secondly, to\n      determine the effect of Isoprinosine in decreasing the severity and/or incidence of lesser\n      opportunistic infections and/or other conditions associated with ARC."
        }, 
        "brief_title": "A Multi-Center Randomized Double-Blind Placebo-Controlled Study To Investigate the Effect of Isoprinosine in Patients With AIDS Related Complex (ARC)", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "AIDS-Related Complex"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Exclusion Criteria\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Cardiac glycosides.\n\n        Patients with the following are excluded:\n\n          -  AIDS.\n\n          -  Presenting with chronic candida infection-colo/rectal, oral/pharyngeal, cutaneous\n             (finger/toenails) - for = or > 3 months who have not responded to therapy.\n\n          -  Critical illness.\n\n          -  Hemophilia.\n\n        Prior Medication:\n\n        Excluded within 1 month of study entry:\n\n          -  Steroids.\n\n          -  Cytotoxic immunosuppressive agents.\n\n          -  Radiotherapy and/or systemic antiviral medication.\n\n          -  Immunomodulators (including Isoprinosine).\n\n        Prior Treatment:\n\n        Excluded within 1 month of study entry:\n\n          -  Radiotherapy.\n\n        History of gout, uric acid urolithiasis, uric acid nephrolithiasis, or renal dysfunction.\n\n          -  Lymphoid malignancy.\n\n        Homosexual male patients with AIDS related complex (ARC).\n\n        Current IV drug abuse."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002060", 
            "org_study_id": "008D", 
            "secondary_id": "ISO-111-USA"
        }, 
        "intervention": {
            "intervention_name": "Inosine pranobex", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Inosine Pranobex"
        }, 
        "keyword": [
            "AIDS-Related Opportunistic Infections", 
            "Inosine Pranobex", 
            "Homosexuality", 
            "Acquired Immunodeficiency Syndrome", 
            "AIDS-Related Complex"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Laguna Hills", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "92656"
                }, 
                "name": "Newport Pharmaceuticals International Inc"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Multi-Center Randomized Double-Blind Placebo-Controlled Study To Investigate the Effect of Isoprinosine in Patients With AIDS Related Complex (ARC)", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002060"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Newport Pharmaceuticals International", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 1989"
    }, 
    "geocoordinates": {
        "Newport Pharmaceuticals International Inc": "33.599 -117.699"
    }
}